Nuzenio

Cabozantinib

Cabozantinib news intelligence with latest source-attributed stories, timeline, related explainers, connected entities, source diversity, and FAQ.

topic 17 latest news signals 13 publisher sources 100/100 entity strength

Latest news

Exelixis Inc (EXEL) (Q2 2026) Earnings Call Highlights: Strong Cabozantinib Growth Offsets NET ... - Yahoo FinanceYahoo Finance · Thu, 06 Aug 2026 05:04:06 GMT Exelixis Q2 2026 earnings: Cabozantinib growth lifts revenue and EPS - TradingKeyTradingKey · Wed, 05 Aug 2026 20:32:53 GMT EXEL: Q2 2026 saw revenue and net income growth, robust cabozantinib sales, and expanded R&D pipeline - TradingViewTradingView · Wed, 05 Aug 2026 20:21:16 GMT Experts Debate PD-1 Rechallenge After ICI Progression in RCC - Targeted OncologyTargeted Oncology · Wed, 05 Aug 2026 20:05:40 GMT Exelixis Announces Second Quarter 2026 Financial Results and Provides Corporate Update - Business WireBusiness Wire · Wed, 05 Aug 2026 20:05:00 GMT Salt-Formulation Cabozantinib Capsules Receive FDA Tentative Approval in RCC, HCC, epNET - CancerNetworkCancerNetwork · Mon, 03 Aug 2026 15:33:29 GMT Darlifarnib Plus Cabozantinib Yields ORRs Up to 50% in Cabozantinib-Naive ccRCC - OncLiveOncLive · Mon, 03 Aug 2026 12:07:09 GMT FDA Tentative Approval for Omcazio: A New Cabozantinib Capsule Formulation - Oncology Nursing NewsOncology Nursing News · Fri, 31 Jul 2026 17:18:13 GMT

Timeline

Thu, 06 Aug 2026 05:04:06 GMTExelixis Inc (EXEL) (Q2 2026) Earnings Call Highlights: Strong Cabozantinib Growth Offsets NET ... - Yahoo Finance

Wed, 05 Aug 2026 20:32:53 GMTExelixis Q2 2026 earnings: Cabozantinib growth lifts revenue and EPS - TradingKey

Wed, 05 Aug 2026 20:21:16 GMTEXEL: Q2 2026 saw revenue and net income growth, robust cabozantinib sales, and expanded R&D pipeline - TradingView

Wed, 05 Aug 2026 20:05:40 GMTExperts Debate PD-1 Rechallenge After ICI Progression in RCC - Targeted Oncology

Wed, 05 Aug 2026 20:05:00 GMTExelixis Announces Second Quarter 2026 Financial Results and Provides Corporate Update - Business Wire

Mon, 03 Aug 2026 15:33:29 GMTSalt-Formulation Cabozantinib Capsules Receive FDA Tentative Approval in RCC, HCC, epNET - CancerNetwork

Related explainers

ElectionsElection stories need careful handling because polls, turnout, legal challenges, and campaign claims can change quickly.HealthHealth stories help readers understand public-health signals, medical research, hospital systems, medicines, disease updates, and safety guidance.HealthcareHealthcare stories can affect personal decisions, so Nuzenio treats them as information that should be checked with original sources and professionals.

Connected entities

RCC6 live mentions Darlifarnib Plus Cabozantinib4 live mentions EXEL3 live mentions Progression3 live mentions Approval3 live mentions FDA Tentative Approval3 live mentions Earnings Call Highlights2 live mentions Strong Cabozantinib Growth2 live mentions Offsets NET2 live mentions Rechallenge After ICI2 live mentions

FAQ

What does this page track?

Latest RSS headlines, source names, timestamps, related explainers, connected entities, and timeline signals for Cabozantinib.

Why might this page be noindex?

Nuzenio only indexes entity pages after enough useful source-attributed coverage and source diversity exists.

Where should readers verify facts?

Open the original publisher links from each story for full reporting, quotes, figures, images, corrections, and updates.

Source diversity

13 distinct publisher/source names are currently connected to this entity page.